Viewing nowEmpagliflozin 10 mg Tablet (Empagliflozin)
Empagliflozin 10mg
Tablet · Prescription medication
Dongwha Pharmaceutical Co., Ltd.

MFDS item code 202102364 · Approved 2021.03.16 · Insurance code 642707100
Improvement of glycemic control in adults with type 2 diabetes mellitus
This medication is used in combination with dietary and exercise therapy to improve blood sugar control in adults with type 2 diabetes. It may initially be administered as monotherapy, but if blood sugar control is insufficient with monotherapy, it will be used in conjunction with metformin or other diabetes medications. It can particularly be used alongside metformin, pioglitazone, sulfonylureas, insulin, or the DPP-4 inhibitor linagliptin. In patients with type 2 diabetes accompanied by cardiovascular disease, administration should be based on expert guidance. This medication is used to enhance blood sugar control and improve diabetes treatment effectiveness.
The recommended dose of this medicine is 10 mg once daily, whether used as monotherapy or as add-on combination therapy with other antihyperglycemic agents, such as insulin. If 10 mg of this medicine is well tolerated and additional glycemic control is needed, the dose may be increased to 25 mg once daily. When this medicine is administered with a sulfonylurea or insulin, reducing the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, section 3, Adverse Reactions). This medicine may be taken with or without food. Swallow the tablet whole. If you miss a dose, take it as soon as you remember. Do not take a double dose in one day. Special populations • Patients with renal impairment No dosage adjustment is necessary in patients with mild renal impairment. Treatment with this medicine should not be initiated in patients with an estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73m2 [or CrCl < 60 ml/min]. In patients who tolerate this medicine well but have a persistently reduced glomerular filtration rate of < 60ml/min/1.73m2 [or CrCl < 60 ml/min], the dose should be adjusted to or maintained at 10 mg once daily. Discontinue this medicine if the glomerular filtration rate decreases to < 45 ml/min/1.73m2 [or CrCl < 45 ml/min]. Do not use this medicine in patients with end-stage renal disease (ESRD) or those on dialysis, as efficacy is not expected. • Patients with hepatic impairment No dosage adjustment is necessary in patients with mild or moderate hepatic impairment. Use of this medicine is not recommended in patients with severe hepatic impairment, as it has not been studied in this population. • Older adults No dosage adjustment based on age is necessary. Renal function and the risk of volume depletion should be considered in patients aged 75 years or older. Initiation of this medicine is not recommended in patients aged 85 years or older because clinical experience is limited (see Precautions for Use, section 4, General Precautions).
This medication should not be used in patients with an allergic reaction to the active ingredient or any of its components. Do not administer this medication to patients with type 1 diabetes or diabetic ketoacidosis. This medication is not to be used in patients with severely impaired renal function, that is, those with a glomerular filtration rate of less than 30 mL/min/1.73m² or in those with end-stage renal disease or undergoing dialysis. This medication contains lactose, so it should not be given to patients with genetic conditions such as galactose intolerance, lactose deficiency, or glucose-galactose malabsorption. Caution is needed in patients with somewhat impaired renal function, and it is advisable not to initiate this medication in patients with a glomerular filtration rate of less than 60 mL/min/1.73m². If renal function continues to fall below 60 mL/min/1.73m², dosage adjustment or discontinuation of the medication is necessary. This medication is not expected to be effective in patients with end-stage renal disease or those on dialysis. As this medication can affect kidney function, it is important to regularly monitor renal function before and during administration. In patients with heart failure, especially those with mild to moderate severity (NYHA class I-II), careful administration is required, and it is not recommended in patients of severe severity (NYHA class III-IV). When used in combination with insulin or insulin secretagogues such as sulfonylureas, there may be an increased risk of hypoglycemia, so dosage adjustment may be necessary in these cases. Patients should be aware of hypoglycemic symptoms while taking this medication, especially when used with insulin or insulin secretagogues. This medication may lead to side effects such as genital infections, urinary tract infections, and increased urination, so if any unusual symptoms occur, immediate consultation with medical personnel is necessary. This medication may cause hypotension or dehydration related to decreased fluid volume, thus caution should be exercised particularly in the elderly or those with low blood pressure. In severe cases, metabolic acidosis known as ketoacidosis may occur, so prompt treatment is required if symptoms occur, necessitating quick testing. It is advisable for pregnant women not to take this medication, and treatment should be discontinued upon confirmation of pregnancy. Breastfeeding women are also recommended to stop nursing if they are taking this medication. The safety and efficacy of this medication have not been established in children under 18 years of age, so it is not used in this population. No specific toxic symptoms have been reported in cases of overdose, but appropriate treatment is necessary depending on the clinical condition. This medication should be stored out of reach of children and it is advisable not to transfer it to another container. There is a risk of hypoglycemia when operating machinery or driving, particularly when used with insulin, so caution is advised. Regular monitoring of kidney function and blood sugar levels during treatment with this medication is important. Additionally, foot care should be emphasized, and if symptoms such as pain, redness, or swelling in the perineum occur, medical personnel should be informed immediately.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to prevent exposure to air and moisture, and it is recommended to keep it at room temperature between 1 and 30 degrees Celsius. Storing it this way can maintain the effectiveness of the medication and prevent degradation.
Light yellow, double convex, round film-coated tablet
30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowEmpagliflozin 10mg
Tablet · Prescription medication
Dongwha Pharmaceutical Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Boehringer Ingelheim Korea Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Boehringer Ingelheim Korea Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Donggu Bio Pharmaceutical Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Dong Gu Bio Pharmaceutical Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Korea Prime Pharmaceuticals Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Korea Prime Pharmaceutical Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Kips Biopharma Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.